Epoch Investment Partners Inc. Sells 21,610 Shares of United Therapeutics Corporation $UTHR

Epoch Investment Partners Inc. lowered its position in United Therapeutics Corporation (NASDAQ:UTHR) by 15.2% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 120,682 shares of the biotechnology company’s stock after selling 21,610 shares during the period. Epoch Investment Partners Inc.’s holdings in United Therapeutics were worth $71,562,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the company. Geneos Wealth Management Inc. grew its stake in shares of United Therapeutics by 141.7% during the 1st quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock valued at $45,000 after acquiring an additional 85 shares during the period. Northwestern Mutual Wealth Management Co. lifted its holdings in United Therapeutics by 18.8% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 443 shares of the biotechnology company’s stock valued at $127,000 after purchasing an additional 70 shares in the last quarter. Jump Financial LLC purchased a new position in United Therapeutics during the second quarter valued at approximately $277,000. Cerity Partners LLC boosted its position in shares of United Therapeutics by 77.3% in the second quarter. Cerity Partners LLC now owns 12,843 shares of the biotechnology company’s stock worth $3,691,000 after purchasing an additional 5,600 shares during the period. Finally, Bank of Nova Scotia boosted its position in shares of United Therapeutics by 6.9% in the second quarter. Bank of Nova Scotia now owns 1,628 shares of the biotechnology company’s stock worth $468,000 after purchasing an additional 105 shares during the period. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Insiders Place Their Bets

In other United Therapeutics news, CFO James Edgemond sold 10,000 shares of United Therapeutics stock in a transaction that occurred on Thursday, May 7th. The stock was sold at an average price of $578.58, for a total value of $5,785,800.00. Following the sale, the chief financial officer owned 18,876 shares of the company’s stock, valued at $10,921,276.08. The trade was a 34.63% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In the last three months, insiders sold 513,333 shares of company stock worth $286,933,042. Company insiders own 8.60% of the company’s stock.

United Therapeutics Stock Performance

Shares of NASDAQ UTHR opened at $528.47 on Friday. The company has a market cap of $22.43 billion, a P/E ratio of 19.51, a P/E/G ratio of 1.77 and a beta of 0.58. United Therapeutics Corporation has a 52-week low of $272.12 and a 52-week high of $609.35. The firm’s fifty day moving average is $547.88 and its two-hundred day moving average is $531.39.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing the consensus estimate of $7.00 by ($1.18). The firm had revenue of $781.50 million during the quarter, compared to the consensus estimate of $797.40 million. United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The company’s revenue for the quarter was down 1.6% compared to the same quarter last year. During the same period last year, the firm posted $6.63 earnings per share. As a group, analysts forecast that United Therapeutics Corporation will post 26.63 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts have recently commented on the stock. Bank of America decreased their price objective on shares of United Therapeutics from $620.00 to $613.00 and set a “neutral” rating on the stock in a research report on Friday, July 10th. HC Wainwright upped their target price on shares of United Therapeutics from $600.00 to $660.00 and gave the stock a “buy” rating in a report on Tuesday, March 31st. TD Cowen reiterated a “buy” rating on shares of United Therapeutics in a research note on Thursday, May 21st. Wells Fargo & Company raised United Therapeutics from an “equal weight” rating to an “overweight” rating and raised their price target for the company from $575.00 to $735.00 in a report on Thursday, May 7th. Finally, Raymond James Financial began coverage on United Therapeutics in a research report on Friday, April 10th. They issued an “outperform” rating and a $700.00 price objective on the stock. Eleven analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat.com, United Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $648.33.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.